Taken together, these discoveries suggest that CaV1.3can provide a novel mechanism and target for regulating excess aldosterone secretionand may be a novel way of treating hyperaldosteronism, especially those caused byZG-like APAs with a CaV1.3 mutation. This evidence concerns the gene CACNA1D and hyperaldosteronism.